Affiliation: | a Linder Research Center, Cincinnati, Ohio, USA b St. Joseph Medical Center, Baltimore, Maryland, USA c St. Vincent’s Hospital, Indianapolis, Indiana, USA d North Ohio Heart Center, Elyria, Ohio, USA e St. Francis Hospital, Roslyn, New York, USA f Riverside Methodist Hospital, Columbus, Ohio, USA g Guidant Corporation, Santa Clara, California, USA h Washington Hospital Center, Washington, DC, USA i Lenox Hill Hospital, New York, New York, USA |
Abstract: | The MULTI-LINK DUET is the next generation MULTI-LINK stent with modified strut geometry. Safety and efficacy of the MULTI-LINK DUET were evaluated in a prospective multicenter registry and were compared with prior MULTI-LINK stent experience from the ASCENT randomized trial. A total of 270 patients received 302 MULTI-LINK DUET stents and were evaluated using a composite primary end point of major cardiac events (death, Q-wave and non–Q-wave myocardial infarction, and requirement for coronary revascularization) attributable to the target stenosis cumulative to 30 days following enrollment. Quantitative coronary angiography was performed at a mean follow-up of 6 ± 2 (±SD) months. No difference in primary end point or in angiographic restenosis to 6 months was observed between MULTI-LINK DUET and MULTI-LINK experiences. The MULTI-LINK DUET demonstrated improved device and procedural success, less postprocedural in-stent stenosis, larger postprocedural minimal lumen diameter, and fewer postprocedural marginal dissections compared with the MULTI-LINK stent. Multivariate regression modeling identified stent length, diabetes mellitus, poststent minimal lumen diameter, lesion eccentricity, and current smoking as independent predictors of in-stent restenosis. Thus, the MULTI-LINK DUET Registry demonstrates enhanced procedural performance with clinical and angiographic outcomes similar to those previously observed for the MULTI-LINK stent in the ASCENT randomized trial. |